Marburg vaccine shows promising results in first-in-human study

Low-Res_Marburg SEM.jpg

Source: NIAID

An experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial, according to a new paper.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE